Just a moment, the page is loading...

*EISAI-E7080-G000-205 Ph2




An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment
lenvatinib
E7080-G000-205 Ph2
NCT01136733
EU CTR 2010-019484-10
Metastatic Renal Cell Carcinoma
Phase 2
 
Sharing of clinical data is prevented for the following countries; Czech Republic.
November 2017